Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.17 USD
Change Today -0.006 / -3.32%
Volume 2.7K
GOVX On Other Exchanges
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

geovax labs inc (GOVX) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/14/14 - $0.51
52 Week Low
12/18/14 - $0.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GEOVAX LABS INC (GOVX)

Related News

No related news articles were found.

geovax labs inc (GOVX) Related Businessweek News

No Related Businessweek News Found

geovax labs inc (GOVX) Details

GeoVax Labs, Inc. operates as a biotechnology company. The company’s develops vaccines that prevent and fight human immunodeficiency virus (HIV) infections that result in acquired immunodeficiency syndrome (AIDS). Its vaccines incorporate two delivery components, including a recombinant DNA and recombinant poxvirus, known as modified vaccinia Ankara, which deliver genes that encode inactivated HIV derived proteins to the immune system. The company’s vaccines under development addressing the clade B subtype of the HIV virus includes GOVX-B11 and GOVX-B21 vaccines that are n Phase I clinical trials to prevent HIV infection, and to serve as a therapy for individuals who are already infected with HIV. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

5 Employees
Last Reported Date: 03/20/15
Founded in 2001

geovax labs inc (GOVX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $174.2K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $212.6K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: $214.6K
Compensation as of Fiscal Year 2014.

geovax labs inc (GOVX) Key Developments

GeoVax Labs, Inc. Appoints Randal D. Chase to Board of Directors

GeoVax Labs, Inc. announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. Dr. Chase, 65, currently serves as a business advisor and consultant to companies in the life science sector. From 2006 to 2011, he served as President and Chief Executive Officer of Immunovaccine, Inc. Dr. Chase is also a former president of Shire Biologics, North American Vaccine, Pasteur Merieux Connaught, and Quadra Logic Technologies, Inc. He currently serves as Chairman of the Board for Medimabs, Inc.

GeoVax Labs, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

GeoVax Labs, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported grant revenue of $883,000 against $2,418,000 a year ago. Loss from operations was $2,738,000 against $2,289,000 a year ago. Net loss was $2,734,000 against $2,285,000 a year ago. Net loss per common share was $0.10 against $0.11 a year ago.

GeoVax Labs, Inc. Provides Update on Ebola Virus Vaccine Development Program

GeoVax Labs, Inc. provided an update on its Ebola virus vaccine development program. In October 2014, GeoVax announced its initiation of a new program for the development of vaccines to prevent Ebola virus infection. GeoVax is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. GOVX-E301 is being developed as a monovalent vaccine for the Zaire strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed as a trivalent vaccine for protection against all three versions of Ebola known to be lethal in humans (Zaire, Sudan and Bundibugyo). Both GOVX-E301 and GOVX-E302 utilize GeoVax's recombinant modified vaccinia Ankara (MVA) platform to expresses virus-like particles (VLPs) in the person being vaccinated. Since initiation of its Ebola vaccine program, GeoVax has successfully designed its MVA-based vaccine vector for the Zaire strain of Ebola using the most current genetic sequences from the ongoing epidemic. The Company has demonstrated that its vaccine produces VLPs in vaccine-expressing human cells, an important milestone in the vaccine's development. GeoVax believes that MVA-expressed VLPs, which display the virus's surface protein (glycoprotein), will be highly effective at eliciting antibody capable of preventing and controlling Ebola virus infections. GeoVax's goals for 2015 include completion of initial immunogenicity studies in small animals, followed by proof-of-concept challenge studies. The company expects to begin challenge studies in non-human primates in late 2015. Simultaneously, GeoVax will be advancing its vaccine manufacturing and test methods, with the goal of initiating human clinical testing in 2016.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GOVX:US $0.17 USD -0.006

GOVX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr359.00 DKK +23.00
CSL Ltd A$91.85 AUD 0.00
Emergent Biosolutions Inc $28.52 USD +0.67
Green Cross Corp/South Korea 176,000 KRW +5,000
Solvay SA €134.00 EUR +0.95
View Industry Companies

Industry Analysis


Industry Average

Valuation GOVX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.1x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GEOVAX LABS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at